MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-13-2026
Biomerica EPS Ratio 2011-2026 | BMRA
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Biomerica
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.16 | -2.84 | -0.5 | -0.36 | -0.62 | -0.26 | -0.26 | -0.17 | -0.11 | -0.2 | -0.04 | -0.03 | 0.08 | 0.08 | 0.02 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.08 | -2.84 | -0.491 |
Quarterly EPS Ratio Biomerica
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.44 | -0.45 | - | - | -0.48 | -0.06 | -0.63 | - | -0.11 | -0.09 | -0.07 | - | -0.12 | -0.12 | -0.16 | -0.28 | -0.01 | -0.09 | -0.12 | -0.21 | -0.18 | -0.15 | -0.16 | -0.13 | -0.14 | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 | -0.03 | -0.02 | -0.03 | -0.02 | -0.02 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.03 | -0.02 | 0.03 | 0.04 | 0.03 | 0.04 | 0.03 | 0.02 | 0.03 | 0.02 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.04 | -0.63 | -0.0839 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-2.06 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
-0.14 | - | -61.36 % | $ 2.46 M |  USA |
 |
Agilent Technologies
A
|
3.98 | $ 119.77 | - | $ 36.4 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
-14.2 | $ 20.56 | - | $ 221 M |  China |
 |
Check-Cap Ltd.
CHEK
|
4.3 | - | - | $ 9.42 M |  Israel |
 |
Aspira Women's Health
AWH
|
-0.37 | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-1.89 | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-0.72 | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-3.09 | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-0.4 | $ 17.57 | - | $ 936 M | USA |
 |
NeoGenomics
NEO
|
-0.84 | $ 8.68 | - | $ 1.11 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
3.67 | $ 29.09 | - | $ 20 B |  Niderland |
|
Akumin
AKU
|
-1.75 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Exact Sciences Corporation
EXAS
|
-1.1 | - | - | $ 19.8 B | USA |
 |
Enzo Biochem
ENZ
|
-0.51 | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
-35.2 | $ 1.42 | - | $ 1.89 M | USA |
 |
Senseonics Holdings
SENS
|
-1.66 | $ 6.9 | - | $ 288 M | USA |
 |
Soleno Therapeutics
SLNO
|
0.4 | $ 52.57 | - | $ 2.67 B | USA |
 |
Castle Biosciences
CSTL
|
0.66 | $ 24.62 | - | $ 684 M | USA |
 |
Neuronetics
STIM
|
-0.59 | $ 1.39 | - | $ 91.7 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.12 | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
-0.08 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.08 | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
-2.91 | $ 180.56 | - | $ 8.95 B | USA |
 |
Thermo Fisher Scientific
TMO
|
17.8 | $ 531.67 | - | $ 200 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-1.3 | $ 57.62 | - | $ 3.45 B | USA |
 |
Danaher Corporation
DHR
|
5.07 | $ 198.14 | - | $ 141 B | USA |
 |
Interpace Biosciences
IDXG
|
5.55 | $ 2.2 | - | $ 9.73 M | USA |
 |
Heska Corporation
HSKA
|
-1.92 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-24.3 | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-7.69 | $ 132.26 | - | $ 21 B | USA |
 |
Fulgent Genetics
FLGT
|
-1.41 | $ 16.17 | - | $ 489 M | USA |
 |
Waters Corporation
WAT
|
3.78 | $ 326.2 | - | $ 19.4 B | USA |
 |
Guardant Health
GH
|
-3.32 | $ 84.86 | - | $ 10.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.96 | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
-0.34 | $ 2.93 | - | $ 95.1 K | USA |
 |
Medpace Holdings
MEDP
|
15.6 | $ 518.54 | - | $ 15 B | USA |
 |
ICON Public Limited Company
ICLR
|
9.6 | $ 116.5 | - | $ 9.61 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
10.5 | $ 266.73 | - | $ 22.2 B | USA |
 |
Motus GI Holdings
MOTS
|
-15.9 | - | -34.28 % | $ 263 K | Israel |
 |
Celcuity
CELC
|
-3.79 | $ 123.47 | - | $ 5.77 B | USA |
 |
Myriad Genetics
MYGN
|
-3.95 | $ 5.19 | - | $ 481 M | USA |
 |
Lantheus Holdings
LNTH
|
3.46 | $ 83.94 | - | $ 5.67 B | USA |
 |
Neogen Corporation
NEOG
|
-5.03 | $ 9.42 | - | $ 2.04 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
8.87 | $ 191.42 | - | $ 21.2 B | USA |